ASCO GU 2023

REVIEW UroToday

Viewing 1-20 of 190 articles

ASCO GU 2023: The Ever-Changing Pathologic Classification of Renal Cell Carcinoma

ASCO GU 2023: Sequencing Systemic Therapies and Looking to the Horizon for Metastatic Urothelial Carcinoma

ASCO GU 2023: Radiation Therapy in Oligometastatic and Local Recurrence Urothelial Carcinoma: The What, Why, and How

ASCO GU 2023: Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate in Metastatic Renal Cell Carcinoma.

ASCO GU 2023: Identifying Prostate Cancer Patient Subgroups Based on Their Preferences for Key Attributes of Androgen Deprivation Therapies

ASCO GU 2023: Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Data Presented at ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced RCC: 3-Year Follow-up from the Phase 3 CheckMate 9ER Trial

ASCO GU 2023: ZIRCON: Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma

ASCO GU 2023: Evaluation of Deep Learning Techniques in RNA Sequencing Data for the Prediction of Response to Immune Checkpoint Inhibitors in Patients with Metastatic Renal Cell Cancer (mRCC)

ASCO GU 2023: Overall Survival and Efficacy Results of Second-Line Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated in the Randomized Phase II BIONIKK Trial

ASCO GU 2023: A Phase II Trial of Combination of PD-1 Immune Checkpoint Inhibition with All-Lesion Stereotactic Radiation in Oligometastatic Renal Cell Carcinoma

ASCO GU 2023: Treatment-Free Survival Outcomes from the Phase II Study of Nivolumab and Salvage Nivolumab + Ipilimumab in Advanced Clear Cell Renal Cell Carcinoma

ASCO GU 2023: Adjuvant Pembrolizumab for Renal Cell Carcinoma (RCC) Across UCLA Integrated Staging System Risk Groups and Disease Stage: Subgroup Analysis from the KEYNOTE-564 Study

ASCO GU 2023: European Association of Urology Testicular Cancer Guidelines Panel: A New Prognostic Factor Risk Group Classification for Patients with Clinical Stage 1 Seminoma in Active Surveillance

ASCO GU 2023: Safety and Efficacy of Immune Checkpoint Inhibitors in Advanced Penile Squamous Cell Carcinoma: An International Study from the Global Society of Rare Genitourinary Tumors

ASCO GU 2023: Treatment-Free Survival Outcomes from the Phase II Study of Nivolumab and Salvage Nivolumab + Ipilimumab in Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

ASCO GU 2023: Accuracy of Fully Automated, AI-Generated Models Compared with Validated Clinical Model to Predict Post-Operative Glomerular Filtration Rate After Renal Surgery

ASCO GU 2023: Burden of Surgeries and Surgical Complications in Patients with Von Hippel Lindau (VHL) Disease Before and After Treatment with Belzutifan

ASCO GU 2023: C-Reactive Protein as a Predictive Marker for Outcomes with Avelumab + Axitinib in Patients with Poor-Risk Advanced Renal Cell Carcinoma: Exploratory Analysis from JAVELIN Renal 101

1
2
3
4
5
6
7
8
9
10